The FDA has granted clearance to the IND applications for both the therapeutic ( [ 225 Ac]Ac-AKY-1189) and imaging ( [ 64 ...

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer ...

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring ...

Papaverine, an investigational drug shown to sensitise tumor cells to radiation therapy by blocking oxygen consumption in tumor cells in preclinical and ongoing clinical trials, is now being tested in ...

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ...

During a live event, Chandler H. Park, MD, and event participants looked at quality of life, tolerability, and rechallenging ...

START and OneOncology launch 3 new early-phase trial sites, expanding access to new cancer research in community oncology ...

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual ...